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Summary.-The compound 125IUdR can be incorporated in a stable form into the DNA of cells. The isotope is released if labelled cells or their progeny die. Consequently the rate of 1251 excretion from mice can be used to follow the fate of labelled cells in vivo. Using these principles we show:
(1) Sufficient label can be incorporated in vitro into both fresh and cryopreserved human leukaemic myeloblasts, in non-toxic concentrations, to allow their survival in mice to be estimated by whole-body counting;
(2) The release of isotope from labelled cells is sufficiently slow to offer reasonable expectation that this technique can be used for assessing the sensitivity of myeloblasts to cytotoxic agents in vivo (an application described in the second paper in this series, Sonis, Falcao and MacLennon, 1977) ; ( 3) The rate of 1251 excretion from mice injected with myeloblasts from different donors varies. This probably reflects different rates of spontaneous death of injected myeloblasts; (4) Active rejection of myeloblasts starts within 48 h of their injection into mice; (5) Indirect evidence that phagocytic cells may be active agents in myeloblast destruction in mice; (6) Various methods of immunologically depriving mice were assessed to see if they would result in a useful increase in survival of injected human myeloblasts. We conclude that there is little advantage and some limitations in using mice thus deprived;
(7) One of the agents used for immunological deprivation-silica powdermarkedly decreased the rate of 125I loss from mice injected with labelled killed myeloblasts. This experience emphasizes the importance of including the killed-cell control in this assay.
THE overall remission rate in acute of sensitivity to drugs, is disappointingly myeloblastic leukaemia in many centres high.
is over 50%. However, the number of With this in mind, we have set out to patients who survive the hazards of the establish a technique which could be used first few weeks of treatment, but still to assess the sensitivity of individual fail to achieve remission because of lack patients' myeloblasts to various cyto-toxic agents in vivo. The model we describe labels patients' leukaemic myeloblasts in vitro with the thymidine analogue 5-12 5odo-2'-deoxyuridine (12 5IUdR In each experiment, groups of 4-5 animals of the same sex and age wN-ere utilised.
Uptake of the iodine by the thyroid was avoided by giving 0-1% KI in the drinking water, 2 days before the labelled cells were injected, and for the duration of the experiment.
Three to five x 107 cells in 1 ml of RPAII were injected i.p. and the radioactivity of the whole body was measured in a large Nal well-counter, immediately after injection and daily thereafter, using the technique of Hughes et al. (1964) .
Effect of serum on phytohaemagylutininstimulate-I blastogenesis.-Fresh frozen serum from AML patients was tested for its ability to modify PHA-stimulated blastogenesis of normal human lymphocytes. The test was performed using a modification of the whole-
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DRUG SENSITIVITY OF HUMAN LEUKAEMIC AIYELOBLASTS. I blood assay described by Maini et al. (1973) . One tenth of a ml of defibrinated whole blood, 0-1 ml of test serum, 0 7 ml of medium Harvesting cultures labelled with IUdR for counting in vitro.-Such cultures were centrifuged and the pellet was resuspended in 500 trichloroacetic acid (TCA) at 4°C. The precipitate was then centrifuged, washed in TCA at 4°C and recentrifuged. The supernatant was discarded and the residue counted in a Wallac well scintillation counter. Irradiated mice.-Mice confined in a narrow perspex cage received 800 rad whole-body irradiation from a 60CO source at 45 rad/min. Animals were used 3 days after irradiation.
The mortality due to irradiation alone was 300/o in the first week (most deaths occur onl Days 5 and 6).
Thymectomised, irradiated, bone-marrow reconstituted (B) mice.-Mice were thymectomised at 8 weeks of age following the technique of Miller (1960) . Two weeks later they were given 850 rad whole-body irradiation from a 220 KV Westinghouse X-ray machine, HVL 0 4 mm Cu, focal distance 100 cm, dose rate 60 rad/min with no added filtration. Within 2-3 h, the mice were injected with 5 x 106 syngeneic bone-marrow cells. These immunologically deprived mice (Davies et al., 1966) were then left for a period of 30 days before being used.
Trypan blue and silica treatment of animals.
-Trypan blue (BDH) wvas dialysed against distilled water and diluted in sterile saline to a concentration of 20 mg/ml. Each animal was injected i.p. with 5 mg and 1 mg at 24 and 3 h respectively before the injection of labelled myeloblasts. One-mg s.c. injections were then given at Days 1 and 3 after myeloblast transfer. This technique is based upon the -work of Hibbs (1975) .
All mice given a single injection of 10 mg of trypan blue died.
Powdered silica.-This was a generous gift from Dr L. Le Bouffant (CERCHAR, B.P.2, 60550 Verneuil-en-Hallatte, France). 8500 of the granules were <1 1um diameter, 12°/ were 1-2 ,um diameter and <10/ were >3 ,tm diameter. The agent was given i.p.
as a single injection of 20 mg 24 h before labelled myeloblasts.
Preparation of peritoneal cells.-Under brief ether anaesthesia the mice were injected i.p. with two 5-ml aliquots of RPMI plus heparin (10 ,u/ml). The free fluid in the peritoneal cavity was then drained into universal bottles (Sterilin). Nucleated cells were counted in an improved Neubauer counting chamber and all "smears" were prepared using a cytocentrifuge (Shandon). These preparations w%Nere fixed in methanol and stained with Giemsa.
Killed cells. Gunson for gifts of AB serum.) Heparinised plasma was found to be as good as serum from the same source. Plasma or serum from AML patients was generally satisfactory as long as it was heatinactivated. Some fresh AML sera markedly inhibited spontaneous uptake of IUdR by both autologous and allogeneic myeloblasts. Consequently we compared the uptake of IUdR by allogeneic myeloblasts, using fresh frozen and heatinactivated sera from each of 53 untreated AML donors (Fig. 3) . The results show that, overall, more IUdR is taken up by myeloblasts in heat-inactivated as opposed to fresh sera. Walker et al. (1973) described an inhibitory effect of sera from patients with AML on the uptake of JUdR by lymphocytes transformed with PHA. We, therefore, compared the effect of fresh frozen serum from each of 34 untreated AML donors on the uptake of IUdR by allogeneic myeloblasts, with their effect on PHA-induced blastogenesis of allogeneic lymphocytes from normal donors (Fig. 3) TdR uptake by lymphocytes cultured with PHA occurred in some sera, there was no correlation between these sera and those associated with poor IUdR uptake by myeloblasts. All the sera used were presentation sera from patients who were subsequently treated with the Barts III regimen of chemotherapy for induction of remission (Powles et al., 1973) . We therefore examined the data for correlation between the degree of these serum effects and the chance of a serum donor achieving remission. No correlation was found in either system, using both the The abso' types, toget' of the perce in Fig. 4 ,lute counts of different cell series of experiments designed to answer ,her with the geometric mean this question involved priming mice with .nt 1251 retention, are shown an i.p. injection of unlabelled myeloblasts here was a rapid but transient 2 days before giving labelled cells. Fig. 5 neutrophil numbers, so that shows the results of one such experiment, he most abundant host cell at where 1251 excretion is compared in h, macrophages had become primed and unprimed mice. It will be .nt host cell and there was seen that the pre-exposure to myeloblasts narked diminution of myelo-results in a 24-h advance of the slope of his stage, frequent myeloblast 1251 excretion. This experiment is highly interactions were seen, in-reproducible, and myeloblasts from a gocytosis of myeloblasts. The different donor are equally effective at between 1251 counts retained inducing accelerated rejection. Although eal myeloblast content, at this these data do not give any information one to postulate that either about the specificity of this reaction they blasts have left the peritoneal do indicate host involvement in the me are firmly adherent to the destruction of myeloblasts. The next peritoneum. Experiments with series of experiments was designed to see ed myeloblasts ( Fig. 5 ) makes whether pretreatment of mice with agents ie explanation that 1251 is which would suppress various types of ned for a significant period cytotoxic immunity could delay myeloblast death. This experiment blast rejection. d once, with similar results.
(iii) The effect of macrophage blocking on rice for active host participation myeloblast rejection.-In preliminary exmnyeloblacst death. The first periments, macrophage blocking was carried out using silica powder injected i.p.
Thk aonrmt ennvidPrah1v dtclard th.cA rath .
-L11 sbJ t5VnUV %VJ1O1%AU1UU1J kA1WJY% V II IUX V S V of 125J loss from animals injected with viable myeloblasts. However, it also markedly reduced the rate of clearance of 125J from mice given killed cells. Consequently, for this practical reason, silica was not considered suitable for use as an agent to delay myeloblast rejection. The second macrophage-blocking agent to be used was trypan blue. This was found by Beck, Lloyd and Griffiths (1967) to block lysosome activity, and Hibbs (1975) used this agent to inhibit tumourcell damage by macrophages. Experiments using this agent, alone and in combination with whole-body irradiation, are shown in Figure 6 . In otherwise normal mice, alone only marginally reduced the speed of myeloblast rejection; i.e., both irradiation and trypan blue were required to produce a significant prolongation of survival of myeloblasts in mice.
(iv) The effect of T-cell depletion on myeloblast rejection.-Mice were deprived of thymus-processed cells as is described in the Methods. These B mice were tested in parallel with controls for their capacity to reject labelled human leukaemic myeloblasts.
There was a decrease in the rate of rejection of about [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Fig. 7 shows a representative experiment indicating that s.c. myeloblasts do indeed survive longer than the same cells injected i.p.
DISCUSSION
The response of mouse tumour cells to chemotherapy, irradiation and host immunity has been studied bv a number of workers using the IUdR labelling technique (Hofer et al., 1969; Hofer, 1970; Porteous and Munro, 1972 al., 1977) reports that, in a limited study, the assay may be able to predict sensitivity to cytosine arabinoside.
The low labelling index of myeloblasts (Crowther et al., 1975) does mean that only a relatively small sample of leukaemic cells is being labelled. It can be argued that this actively dividing fraction may not be representative of all the neoplastic cells. The only answer to this is practical evaluation, and the point is considered further in the next paper. In any case, the labelling procedure used here is likely to be at least as representative of the total neoplasm as cells obtained following prolonged culture in vitro or serial transplantation in immunologically deprived animals.
The main advantages of using an in vivo test system, even if it does cross a species barrier, is that many cytotoxic agents, for example cyclophosphamide and azathioprine, are broken down to active daughter compounds in vivo. Obviously, the model we propose cannot predict an individual's capacity to break down a drug outside neoplastic cells.
There can be little doubt that much of the 125J excretion observed in our studies is due to spontaneous death of myeloblasts. However, there does appear to be some reaction by the mouse to the myeloblasts which accelerates loss of 12 51 following the injection of viable cells. This is shown by the consistent finding that the main slope of 1251 excretion occurred earlier if unlabelled myeloblasts were injected 2 days before the labelled myeloblasts. This cannot just be an effect on release and excretion of iodide from dead cells, as the priming had no effect on the rate of excretion of 125J from mice injected with dead labelled cells. The mechanism involved here is unclear, although a number of the experiments provide an indirect hint that macrophages may be involved. The important conclusion to be drawn from the immunological deprivation experiments is that the techniques of deprivation used do not delay 1251 release sufficiently to be of practical advantage. Indeed, as they are somewhat drastic, they might alter the recipient's capacity to handle cytotoxic agents. In this context, the marked effect of silica on the excretion of iodide following injection of dead labelled cells is a warning that the killed-cell control must be included in all drug evaluation studies.
The growth-inhibiting factors which we describe in this paper have been recognised previously. Balkwill, Pindar and Crowther (1974) found a "complement"-dependent growth-inhibitory factor in a patient with AML. Karp and Burke (1976) have also described an inhibitory effect of this type in leukaemic patients' serum, which acted on both normal and leukaemic bone marrow cells. Walker et al. (1973) described an inhibitory effect of sera from patients with AML on the mitotic response of normal lymphocytes to PHA. It is disappointing that no correlation of these factors with remission achievement was apparent.
In conclusion we feel that the incidence of failure to achieve remission through lack of response to drugs is sufficiently high to justify the development of predictive tests for drug sensitivity in acute myeloblastic leukaemia. The technique described in this study seems to offer a practical approach to predicting sensitivity of an individual patient's myeloblasts to cytotoxic agents.
